ReviewBreast care (Basel, Switzerland)2023
St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer - A Brief Summary of the Consensus Discussion.
Review in Breast care (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Surgeon Perspectives on Axillary Management Following Neoadjuvant Endocrine Therapy: Results from a Qualitative Substudy of the PELOPS Trial.Annals of surgical oncology · 2026Trial
- Population-specific MicroRNA biomarker discovery in breast ductal carcinoma via explainable graph neural multi-omics modeling.BMC cancer · 2026Article
- Multimodal radiomics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer: integration of amide proton transfer weighted imaging in radiomics.BMC medical imaging · 2026Article
- Breast-Conserving Therapy for Multiple Ipsilateral Breast Cancer After Neoadjuvant Systemic Therapy.Annals of surgical oncology · 2026Article
- Evaluating the Role of Artificial Intelligence in Enhancing Multidisciplinary Team Decisions for Breast Cancer Management.European journal of breast health · 2026Article
- ASO Author Reflections: No Further Axillary Treatment is Safe if the Sentinel Nodes are Negative After Neoadjuvant Chemotherapy in cT2 cN1 Breast Cancer.Annals of surgical oncology · 2026Article
- Age-dependent differences in survival of patients with early breast cancer: analysis of SUCCESS A, B, C trials.Archives of gynecology and obstetrics · 2026Article
- Treatment Regimens and Response Rates in Early TNBC: A Review of Real-World Practice in the Second Decade of the 21st Century.The breast journal · 2026Article
- Assessment of treatment outcomes in patients with breast cancer who underwent mastectomy and breast reconstruction with sparing of the areola-nipple complex - single-center analysis.Frontiers in oncology · 2026Article
- Factors influencing oncologists' decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancer.Frontiers in oncology · 2026Article
- Measuring Surgical Waiting Times in Breast Cancer: Admission to Surgery Versus Biopsy Result to Surgery.Healthcare (Basel, Switzerland) · 2025Article
- Article
- Feline Mammary Tumors: A Comprehensive Review of Histological Classification Schemes, Grading Systems, and Prognostic Factors.Veterinary sciences · 2025Review
- Nomogram construction and survival analysis in T3N0M0 breast cancer: a SEER population-based analysis.Scientific reports · 2025Article
- Article
- Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression.Molecular oncology · 2025Review
- A CDE-based data structure for radiotherapeutic decision-making in breast cancer.BMC medical informatics and decision making · 2025Article
- Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value.World journal of experimental medicine · 2025Article
- De-escalation of regional nodal management for breast cancer patients after primary systemic therapy: from radiation oncologist's perspectives.Radiation oncology journal · 2025Article
- DNA Methylation and Demethylation in Triple-Negative Breast Cancer: Associations with Clinicopathological Characteristics and the Chemotherapy Response.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The St. Gallen Consensus Conference on early breast cancer treatment 2023 was again a live event and took place in Vienna, Austria. After 4 years and one virtual event due to the pandemic, more than 2,800 participants from over 100 countries came together in Vienna, and the 2023 St. Gallen/Vienna conference was a great success. Over 3 days, the global faculty reviewed the most important evidence published during the last 2 years and debated over controversial topics, and finally, the consensus votes aimed to define the impact of the new data on everyday routine practice. Focuses of this year's conference were radiotherapy and local management of the axilla, genetics, and their impact on treatment, as well as the role of the immune system and tumor-infiltrating lymphocytes in pathological reports and treatment decision-making. The traditional panel votes were moderated for the first time by Harold Burstein from Boston, and with questions previously voted on and live voting, the panel managed for the most part to clarify the critical questions. This report by editors of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.